- Corporate website
| 
News
Archives
Follow us on :
27/10/08
Launch of a ph.III clinical trial in adults for Oralair Grasses in the US
Operating income expected to remain stable in 2009
07/10/08
Partnership with Catalent and The Medical House
Partnership for commercialization of adrenaline autoinjector in Europe
10/09/08
Stallergenes inaugurates the biggest pharmaceutical allergen production unit in the world
Stallergenes S.A. officially inaugurates its new pharmaceutical production unit, located in Paris area.
27/08/08
First half year 2008 : a 19% increase in operating profit and net profit
Category: Group activities
The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved Stallergenes' half year consolidated financial statement :
27/08/08
Oralair® Grasses 300 IR : Highly positive clinical results in a pharmacodynamic study conducted in an allergen challenge chamber
Category: R&D
24/06/08
Obtention of the market authorization in Germany for Oralair® Grasses
Stallergenes has been granted with the market authorization in Germany for its sublingual desensitisation tablet Oralair® Grasses.
28/07/08
Phase III clinical trial for Staloral® 300 in China
Category: R&D
Stallergenes launches a phase III clinical trial for Staloral® 300 in China
10/06/08
Phase II/III clinical trial on a tablet for desensitisation to mites
Category: R&D
Stallergenes has started a phase II/III clinical trial on a tablet for desensitisation to mites
21/03/08
A new logo for Stallergenes
Category: Group activities
In order to pursue its development and to reach its future objectives, Stallergenes is adopting a new logo.
12/03/08
2007 Results
Category: Group activities, Finance
Further profit growth; Sales up 16%;
Profit before R&D up 19%;
Net profit (group share) up 12%;
Acceleration of R&D expenditure
13/12/07
Partnership for producing mites recombinant allergens
Category: R&D
Partnership agreement between STALLERGENES and PROTEIN’EXPERT
28/11/07
Oralair® Grasses: Positive results of VO52.06 paediatric study
Category: Group activities, Finance
The results of a study on children confirmed the efficacy of the ORALAIR® Grasses sublingual desensitisation product, which is due to receive German market authorisation shortly.
14/05/07
Stallergenes and CMC BIOPHARMACEUTICALS sign manufacturing agreement
Signature of an agreement for development and supply of recombinant Bet v 1 (rBet v 1) purified bulk.
15/03/07
Increase in operating profit and additional R&D efforts
Category: Finance
2006: Another year of growth